Skip to main content
Quest Diagnostics

Changes in Ganglioside Antibody Positivity Rates During the COVID-19 Pandemic

Changes in ganglioside antibody positivity rates during the COVID-19 pandemic

Authors: Racke MK, Niles JK, Lorenz RA, Kaufman HW.

Citation: J. Neuroimmunol. 2022 Jun 15; 367: 577877. Online ahead of print 2022 Apr 22. doi: 10.1016/j.jneuroim.2022.577877.

Specialties: Infectious Disease, Neurology, COVID-19

Download key summary

Related content

Conference Presentation
Changes in Guillain-Barre Syndrome-Associated Ganglioside Antibody Test Results at a National Clinical Laboratory During the COVID-19 Pandemic
Publication
Current State of Pediatric Reference Intervals and the Importance of Correctly Describing the Biochemistry of Child Development: A Review
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Publication
New Cancer Diagnoses Still Lagging in the United States in Second Full Year of COVID-19 Pandemic
Publication
New diagnosis of systemic lupus erythematosus after COVID-19 vaccination: A case report and review of literature
Test FAQ
SARS CoV 2 Antibody Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.